This post was originally published on this site It’s probably not back. But if it is, it’ll kill me. Every six months, I travel to the Bay Area for tests to see if my triple-negative breast cancer is back. It’s nerve-wracking. I’ve already decided I won’t do chemo again; not because I hated chemo —…
This post was originally published on this site When my mom was diagnosed with terminal uterine cancer, she was displeased to say the least. Being diagnosed with Alzheimer’s disease just after witnessing her mother pass away from the terrifying disease in 2014 did not exactly bring out the sunshine, either. But she suddenly saw terminal…
This post was originally published on this site Prostate cancer’s incidence and deadliness has declined or stabilized in much of the world in recent years, with the greatest decrease in risk evident in the U.S., a study reports. These findings were presented at the recent 2019 American Association for Cancer Research (AACR) Annual Meeting, which took…
This post was originally published on this site Some 87 buildings, landmarks, and businesses in the U.S. and Canada turned purple April 13 in an attempt to help raise awareness about sarcoidosis during Sarcoidosis Awareness Month. The initiative is called “Illuminate the Night: Shine a Light on Sarcoidosis,” and was begun by the nonprofit Foundation…
This post was originally published on this site Lynparza (olaparib) tablets have been approved by the European Commission as a standalone treatment for adults with a subset of locally advanced or metastatic breast cancer. The decision follows a recommendation by the Committee for Medicinal Products for Human Use (an arm of the European Medicines Agency), making…
This post was originally published on this site While caregiving for people with Alzheimer’s and other disorders has a significant detrimental impact on caregivers’ immune system, the association is weak — less than 1% — and may not carry clinical significance, a new study shows. “We’re not saying that family caregiving can’t be stressful, but…
This post was originally published on this site Myriad Genetics has submitted the first part of a premarket approval application with the U.S. Food and Drug Administration for myChoice HRD CDx, a diagnostic test designed to identify ovarian cancer patients more likely to benefit from treatment with the PARP inhibitor Zejula (niraparib). Premarket approval is the FDA’s…
This post was originally published on this site The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid leukemia and multiple myeloma, the company announced. The Phase 1/2 trial will be conducted at two clinical centers in Italy — the San Raffaele Hospital in…
This post was originally published on this site Long-term use of oral contraceptives protects women from the most lethal types of ovarian cancers, a large multi-center study has found. The study, “Oral contraceptive use and risk of highly fatal ovarian cancer: Evidence from the Ovarian Cancer Association Consortium,” was recently presented at the 2019 American…
This post was originally published on this site Janssen has submitted an application to Japanese authorities seeking the approval of Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — for the treatment of newly diagnosed multiple myeloma patients ineligible for high-dose chemotherapy and stem cell transplant. The supplemental new drug application, which will be considered under priority review, is based on data from…
